KRAS G12C-mutant cancers | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

84,000 results for “KRAS G12C-mutant cancers”

Trials

View all 72122 →

Active, not recruiting

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

105 participants · First posted Dec 6, 2022

Not yet recruiting

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

69 participants · First posted Dec 19, 2025

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

33 participants · First posted Jul 19, 2021

Drugs

View all 1810 →

KRAS G12C/D/V/G13D program (KRAS-mutated cancers)

Kras Inhibitor (cancers)

KRAS G12C Inhibitor(BioArdis)

Organizations

View all 292 →

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Rein Therapeutics

Aprea Therapeutics

United States

News

View all 9776 →

InxMed Reports Breakthrough Results for Ifebemtinib-Garsorasib Combination in KRAS G12C-Mutant Cancers at ASCO 2025

Merck Launches Phase 3 KANDLELIT-007 Trial for Calderasib-KEYTRUDA QLEX Combination in KRAS G12C-Mutant Lung Cancer

Glecirasib Shows Promise as Novel KRAS G12C Inhibitor in Solid Tumors

Page 1 of 8400